Clinical use of presepsin

Early diagnosis and prognosis

In a reference range study presepsin concentrations were determined in EDTA plasma samples from 119 healthy individuals (age: 21 – 69 years; 60 females and 59 males).
Arithmetric mean: 160 pg/ml (95% CI: 48 – 171 pg/ml) [Spanuth E et al, Ref. 4].
The presepsin values were determined at presentation in the emergency department in patients with sepsis.
Quartiles of presepsin showed a strong association with the 30 day mortality [Spanuth E et al, Ref. 4]:

ROC analysis comparing the accuracy for the prediction of 30-day mortality revealed areas under the receiver operating  characteristics curve (AUC) for presepsin, APACHE II score and procalcitonin of 0.878, 0.815 and 0.661, respectively [Spanuth E et al, Ref. 4].

Presepsin showed superior prognostic accuracy!

Disease monitoring

Presepsin was measured at presentation, at 24 hours and at 72 hours after admission. In patients with favorable outcome within 30 days after admission (n=104) presepsin levels decreased from baseline to 72 hours. In the patient group who experienced adverse outcome (n=36), presepsin levels showed an increasing tendency [Spanuth E et al, Ref. 4].

Disease thresholds

Presepsin determination at admission to the emergency department in 140 septic patients enrolled in a clinical outcome study revealed the following values [Spanuth E et al, Ref. 5]:

For emergency and intensive care use

PATHFAST Presepsin can be measured out of whole blood and is due to the fast turn around time and high prognostic power already at admission suitable for the use in emergency and intensive care units.

→ Sample material: anticoagulated (EDTA/heparin) whole blood or plasma

→ Turn around time: 15 min